Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice

Amano, Toru; Takeda, Takumi; Yano, Haruna; Tamura, Tadafumi

doi:10.1111/j.1365-2133.2007.07796.x

Cited by 14 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moisturizers have less anti-inflammatory activity than PPARα activators, and while topical calcineurin inhibitors display significant anti-inflammatory effects, they compromise both epidermal permeability-barrier functions and antimicrobial barrier function in mice (Kim et al ., 2009). The oral administration of olopatadine hydrochloride has a positive effect on permeability barrier homeostasis and inflammation (Amano et al ., 2007; Tamura et al ., 2008), an observation that is consistent with the known ability of antihistamines (H1 and H2 blockers) to improve barrier function (Ashida et al ., 2001). However, it remains to be determined whether topical administration of olopatadine hydrochloride would also be effective for the treatment of AD, and in addition, it is unclear whether they can prevent the emergence of GC-related side effects.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Combined Peroxisome Proliferator-Activated Receptor-α Ligand and Glucocorticoid Therapy in a Murine Model of Atopic Dermatitis

Hatano

Elias

Crumrine

et al. 2011

Journal of Investigative Dermatology

View full text Add to dashboard Cite

Although topical glucocorticoids (GCs) display potent anti-inflammatory activity in inflamed skin, they also can exert numerous harmful effects on epidermal structure and function. In contrast, topical applications of ligands of peroxisome proliferator-activated receptor-α (PPARα) not only reduce inflammation, and also improve cutaneous barrier homeostasis. Therefore, we examined whether sequential topical GCs followed by topical Wy14643 (a ligand of PPARα) might be more effective than either alone for atopic dermatitis (AD) in a hapten (oxazolone)-induced, murine model with multiple features of AD (Ox-AD). Despite expected anti-inflammatory benefits, topical GC alone induced: i) epidermal thinning; ii) reduced expression of involucrin, loricrin and filaggrin; and iii) allowed outside-to-inside penetration of an epicutaneous tracer. While Wy14643 alone yielded significant therapeutic benefits in mice with mild or moderate Ox-AD, it was less effective in severe Ox-AD. Yet, topical applications of Wy14643 after GC was not only significantly effective comparable to GC alone, but it also prevented GC-induced structural and functional abnormalities in permeability barrier homeostasis. Moreover, rebound flares were largely absent after sequential treatment with GC and Wy14643. Together, these results show that GC and PPARα ligand therapy together is not only effective but also prevents development of GC-induced side effects, including rebound flares, in murine AD.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Combined Peroxisome Proliferator-Activated Receptor-α Ligand and Glucocorticoid Therapy in a Murine Model of Atopic Dermatitis

Hatano

Elias

Crumrine

et al. 2011

Journal of Investigative Dermatology

View full text Add to dashboard Cite

show abstract

“…Importantly, none of the FDA-approved antihistamines antagonize H3R or H4R at standard dosing regimens. In an epicutaneous allergen challenge murine AD model, treatment with the selective H1R antihistamine, olopatadine, not only suppressed inflammation and scratching by inhibiting cytokine/chemokine production (e.g., IL-31, TSLP, TARC) but also improved the skin barrier function [65,66,67,68,69]. Olopatadine has inhibitory effects on the release of inflammatory mediators (e.g., histamine, leukotriene, thromboxane, and tachykinins), which could explain these broad anti-allergic properties [70].…”

Section: Histamine Overviewmentioning

confidence: 99%

Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?

Benedetto

Yoshida

Fridy

et al. 2015

JCM

View full text Add to dashboard Cite

Atopic Dermatitis (AD), the most common chronic inflammatory skin disease, is characterized by an overactive immune response to a host of environmental allergens and dry, itchy skin. Over the past decade important discoveries have demonstrated that AD develops in part from genetic and/or acquired defects in the skin barrier. Histamine is an aminergic neurotransmitter involved in physiologic and pathologic processes such as pruritus, inflammation, and vascular leak. Enhanced histamine release has been observed in the skin of patients with AD and antihistamines are often prescribed for their sedating and anti-itch properties. Recent evidence suggests that histamine also inhibits the terminal differentiation of keratinocytes and impairs the skin barrier, raising the question whether histamine might play a role in AD barrier impairment. This, coupled with the notion that histamine’s effects mediated through the recently identified histamine receptor H4R, may be important in allergic inflammation, has renewed interest in this mediator in allergic diseases. In this paper we summarize the current knowledge on histamine and histamine receptor antagonists in AD and skin barrier function.

show abstract

“…It has been reported that olopatadine attenuates (1) the elevation of various inflammatory cytokines in skin lesions, and (2) the scratching behavior in a mouse model of chronic contact dermatitis induced by repeated hapten challenge [28,29]. Furthermore, olopatadine accelerates the recovery of skin barrier function [30]. We evaluated the antineuritogenic and antipruritic effects of olopatadine in NC/Nga mice with dermatitis.…”

Section: Introductionmentioning

confidence: 99%

Olopatadine Hydrochloride Improves Dermatitis Score and Inhibits Scratch Behavior in NC/Nga Mice

Murota

El-latif²,

Tamura³

et al. 2010

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Control of itch is an important issue in the treatment of atopic dermatitis (AD). Itch is mediated by a variety of pruritogens, including histamine, and promoted by neurite outgrowth in the epidermis of AD patients, probably due to the release of nerve growth factor. Objectives: We investigated the effects of orally administered olopatadine hydrochloride (olopatadine) on itching, itching mediators, and neuritogenic action in a mouse model. Materials and Methods: NC/Nga mice were treated topically with Dermatophagoides farinae body (Dfb) extract twice weekly for 4 weeks to induce AD-like lesions. They were concomitantly given oral olopatadine, distilled deionized water, or topical tacrolimus during the last 2 weeks. Results: Olopatadine significantly suppressed scratching, improved the dermatitis score, inhibited neurite outgrowth, and decreased the elevated inflammatory markers, growth factors and histamine content in the lesional skin, and serum concentration of Dfb-specific IgE. Notably, olopatadine treatment increased semaphorin 3A expression in the epidermis. Conclusions: Our study confirms the pleiotropic effects of olopatadine, i.e. inhibition of inflammation and neurite extension into the epidermis.

show abstract

Olopatadine hydrochloride accelerates the recovery of skin barrier function in mice

Abstract: These results suggest that systemic administration of olopatadine accelerates the recovery of skin barrier function and ameliorates the adverse effects of topical steroids on skin barrier recovery.

Cited by 14 publications

References 31 publications

Efficacy of Combined Peroxisome Proliferator-Activated Receptor-α Ligand and Glucocorticoid Therapy in a Murine Model of Atopic Dermatitis

Efficacy of Combined Peroxisome Proliferator-Activated Receptor-α Ligand and Glucocorticoid Therapy in a Murine Model of Atopic Dermatitis

Histamine and Skin Barrier: Are Histamine Antagonists Useful for the Prevention or Treatment of Atopic Dermatitis?

Olopatadine Hydrochloride Improves Dermatitis Score and Inhibits Scratch Behavior in NC/Nga Mice

Contact Info

Product

Resources

About